Professional Documents
Culture Documents
Treatment of pelvic inflammatory disease (PID) should provide high rates of clinical and microbiological cure
for a range of pathogens and should ultimately prevent reproductive morbidity. Between 1992 and 2006, 5
randomized clinical trials of moxifloxacin (1 trial), ofloxacin (1 trial), clindamycin-ciprofloxacin (1 trial), and
azithromycin (2 trials) treatment among women with mild to moderate PID were found to have clinical cure
rates of 90%97%. Trials of ofloxacin and clindamycin-ciprofloxacin reported rates of cure of Neisseria gonorrhoeae and Chlamydia trachomatis infection of 100%, although microbiological cure data for other pathogens
were not presented. One azithromycin trial reported a 98% eradication of C. trachomatis, N. gonorrhoeae,
Mycoplasma hominis, and anaerobes. Moxifloxacin exhibited high eradication rates for N. gonorrhoeae, C.
trachomatis, M. hominis, Mycobacterium genitalium, and gram-negative anaerobes. Clinical cure rates from 2
doxycycline-metronidazole trials were low (35% and 55%). Although a handful of studies have shown that
monotherapies for PID achieve high rates of clinical cure, the efficacy of these regimens in treating anaerobic
PID and in preventing adverse reproductive sequelae is not fully elucidated.
Table 1. 2006 US Centers for Disease Control and Preventionrecommended outpatient regimens for the treatment
of pelvic inflammatory disease.
Drug
Dosage
Ofloxacin
Levofloxacin
Metronidazole
FLUOROQUINOLONE TRIALS
Table 2 provides a summary of the randomized clinical trials
of treatment for PID published between 1992 and 2006. In
general, these recent treatment trials have focused on monotherapies, which are believed to increase compliance. One randomized trial comparing ofloxacin with cefoxitin plus doxycycline among 249 women with clinically suspected PID
reported high rates of clinical cure or improvement (95% vs.
93%) and eradication of N. gonorrhoeae (100% in both groups)
[16]. Ofloxacin was associated with greater eradication of C.
trachomatis (100% vs. 88%) and a lower prevalence of adverse
effects (7% vs. 15%) [16]. Although anaerobes, aerobes, and
mycoplasmal species were obtained from culture for some
women, data about eradication of pathogens were not presented
[16]. Thus, it is impossible to determine from this study the
microbiological efficacy of ofloxacin in treating PID due to
anaerobic species.
Two nonrandomized studies of laparoscopically confirmed
954 CID 2007:44 (1 April) Haggerty and Ness
Also of interest because of its association with enhanced compliance, single-dose or short-duration azithromycin in the
treatment of PID has been examined in a handful of studies.
Not surprisingly, compliance with single-dose azithromycin
therapy has been reported to be 100% [25]. In a randomized
clinical trial from India of 165 women with clinically suspected
PID, a kit containing 1 tablet of fluconazole (150 mg), 1 tablet
of azithromycin (1 g), and 2 tablets of secnidazole (2 g) was
associated with a PID clinical cure rate of 93%, which is similar
to that found among a group treated with ciprofloxacin plus
tinidazole for 7 days (clinical cure rate, 96%) and better than
that found among women treated with doxycycline plus metronidazole for 1 week (clinical cure rate, 91%) [19]. However,
although this trial showed high rates of clinical cure, data on
microbiological cure were not presented. In a randomized clinical trial in the United Kingdom that compared azithromycin
monotherapy, azithromycin plus metronidazole, and standard
21-day regimens of metronidazole-doxycycline-cefoxitin-probenecid or doxycycline-amoxicillin-clavulanate among 300 patients with PID, azithromycin was found to have a high rate
of clinical success, similar to that of other regimens (97% for
azithromycin monotherapy, compared with 96% for azithromycin-metronidazole and 95% for a comparator regimen) [20].
Moreover, azithromycin provided excellent rates of eradication
of C. trachomatis, N. gonorrhoeae, M. hominis, and anaerobes
[20]. Complicating the interpretation of this study, however,
was the combining of 2 different trials in the analyses. In 1
trial, 500 mg of azithromycin was administered intravenously
on day 1, followed by 250 mg of oral azithromycin for 6 days.
In the other trial, the intravenous protocol was conducted for
2 days, followed by oral azithromycin therapy for 5 days. The
comparator regimens in each trial differed as well. Therefore,
the optimal azithromycin regimen cannot be determined. Furthermore, the dropout rate at the final follow-up visit was
extremely high (78%), and this reduces the validity and generalizability of the microbiological cure evaluation.
Regimen
Year
Moxifloxacin
Comparator: ceftriaxone (250 mg im, single dose) and Dox (100 mg,
1 capsule twice daily) and placebo (2 capsules 3 times daily for
equivalent diseases of Clin) for 14 days
Arredondo et al. [17] 1996 Clin (300 mg, 2 capsules 3 times daily) and Cpfx (250 mg, 1 tablet
twice daily) for 14 days
Ofloxacin
Drug, study
61/64 (95)
65/67 (97)
7% rate of AEs
Clinical cure,
proportion of
patients (%)
Table 2. Randomized clinical trials since 1992 for the treatment of pelvic inflammatory disease.
Comparator: Clin (900 mg iv) plus gentamicin (1.5 mg/kg, following a 166/184 (90) 86% eradication of N. gonorrhoeae, anaerloading dose of 2.0 mg/kg, iv every 8 h for 210 days)
obes, and aerobes
Not reported
Not reported
9/20 (45)
7/20 (35)
1993 Dox (200 mg first day followed by 100 mg daily) and Mtz (500 mg
every 8 h) for 1014 days
Not reported
Not reported
Not reported
101/105 (96) Eradication rate at end of treatment was 24/ 30% rate of AEs causing 4 discontinuations
25 (96%) for C. trachomatis, 5/5 (100%) for
N. gonorrhoeae, 15/18 (83%) for M. hominis, and 11/11 (100%) for anaerobes
Comparators: Mtz (500 mg iv 3 times daily for 1 day) plus Dox (100 88/93 (95)
mg po twice daily for 14 days) plus cefoxitin (2 g im 4 times daily)
plus probenecid (1 g po single dose) or Dox (100 mg po twice
daily for 21 days) plus amoxicillin-clavulanate (1 g iv 3 times daily
for 5 days) plus amoxicillin-clavulanate (500 mg po 3 times daily)
99/102 (97)
42/46 (91)
Comparator: Dox (100 mg) twice daily and Mtz (200 mg) 3 times
daily for 7 days
47/49 (96)
Comparator: Cpfx (500 mg) and tinidazole (600 mg) twice daily for 7
days
2003 Kit containing 1 tablet of fluconazole (150 mg), 1 tablet of azithromy- 43/46 (93)
cin (1 g), and 2 tablets of secnidazole (2 g)
NOTE. AE, adverse event; Clin, clindamycin; Cpfx, ciprofloxacin; Dox, doxycycline; Mtz, metronidazole.
Meropenem
Dox-Mtz
Azithromycin
clinically suspected mild to moderate PID treated with the standard antibiotic regimen of doxycycline and cefoxitin, endometritis and upper genital tract gonococcal and chlamydial infection were not associated with reproductive morbidity [37].
One interpretation is that these antibiotics that are used to treat
modern-day mild to moderate chlamydial and gonococcal PID
limited to the uterus are so effective that reproductive morbidity
is not elevated among women with treated endometritis. However, despite the high rates of clinical cure and eradication of
N. gonorrhoeae and C. trachomatis observed in the PEACH
study at 30 days after treatment [38], rates of infertility (17%)
[38], recurrent PID (14%) [38], and chronic pelvic pain (37%)
[39] were distressingly elevated over the course of follow-up.
This suggests a need to discover and provide coverage against
all possible damaging PID pathogens and also to focus on longterm morbidity in treatment efficacy evaluations.
It is possible that women with nongonococcal PID may be
more likely to experience adverse sequelae. In the PEACH study,
we reported that women with nongonococcal bacteria identified
in the endometrium were generally more likely to experience
reproductive morbidity than were women with gonococcal infection. Infertility rates were 13% for women with N. gonorrhoeae identified, 19% for women with C. trachomatis identified, 22% for women with anaerobic bacteria identified, 27%
for women with U. urealyticum identified, and 17% for women
with M. hominis identified; chronic pelvic pain rates were 27%
for women with N. gonorrhoeae identified, 21% for women
with C. trachomatis identified, 33% for women with anaerobic
bacteria identified, 41% for women with U. urealyticum identified, and 54% for women with M. hominis identified. Similarly, in a study by Brunham et al. [40] of 50 women with
laparoscopically confirmed salpingitis, 54% of women with
nongonococcal infections had future adverse reproductive outcomes, compared with none of the women with gonococcal
infections. Collectively, the PEACH study [37] and the study
by Brunham et al. [40] suggest that, although these regimens
may have high short-term clinical and microbiological cure
rates, the standard antibiotic regimens of doxycycline-cefoxitin
[37], doxycycline-clindamycin [40], and doxycycline-metronidazole [40] may not be optimal for the prevention of adverse
sequelae among women with nongonococcal PID.
Animal models may provide insight into better regimens for
the treatment of nongonococcal PID. Rapid single-dose oral
azithromycin therapy has been found to prevent infertility in
a mouse model of chlamydial salpingitis [41]. Similarly, azithromycin was found to be more effective than doxycycline in
the microbiological cure of C. trachomatis infection and the
prevention of immunopathological upper reproductive tract
damage in a macaque model of PID [42]. Studies of reproductive sequelae following various PID treatment regimens in
humans are needed.
relation between the microbiological makeup of the endometrium and fallopian tube and the unlikelihood of determining
the microbiological flora of the fallopian tube after treatment.
Despite the challenges facing the study of PID due to anaerobic
organisms as a result of the fact that only one-third to onehalf of PID cases are attributed to N. gonorrhoeae and/or C.
trachomatis and the fact that bacterial vaginosis, anaerobic
gram-negative rods, and mycoplasmal bacteria have been identified among women with PID [9, 10, 12, 27, 28], the microbiological efficacy of treatment regimens for both chlamydial
and/or gonococcal and nonchlamydial and/or nongonococcal
PID should be determined. Unfortunately, previous trials of
metronidazole showed it to have limited efficacy, perhaps because poor tolerability limits adherence. Indeed, the highest
rates of adverse effects and study discontinuation in the randomized clinical trials reviewed herein occurred in women who
were assigned to comparator regimens containing metronidazole [1820]. This fact underscores the need for research on
agents for the treatment of PID that are bactericidal for anaerobes. Regimens with shorter duration and monotherapy regimens are promising and may increase compliance and decrease
sequelae. However, there is currently limited evidence for the
recommendation of alternative therapies for the treatment of
anaerobic PID. Although azithromycin provides coverage
against a range of anaerobic and aerobic pathogens (including
black-pigmented gram-negative rods) [20, 29], fluoroquinolones, including ofloxacin, have generally been found to have
limited activity against anaerobes [30, 31]. In a recent trial of
moxifloxacin versus ofloxacin plus metronidazole, moxifloxacin was found to be as clinically efficacious as ofloxacin plus
metronidazole and to exhibit similar cure rates for C. trachomatis and Mycoplasma and better cure rates for N. gonorrhoeae
and gram-negative anaerobes [18]. However, women treated
with moxifloxacin experienced a worse cure rate for grampositive anaerobes [18]. Alternatively, a study has shown azithromycin to be effective for the treatment of anaerobic PID [20].
Clinical cure rates and eradication of anaerobes are similar
among women whose PID is treated with azithromycin alone
and women treated with combination azithromycin-metronidazole (clinical cure rate, 97% vs. 96%; anaerobe eradication
rate, 100% vs. 100%) [20]. This initial study is promising, and
further work may support the use of azithromycin monotherapy for the treatment of anaerobic PID. However, neither azithromycin nor quinolones are optimal for the treatment of gonococcal PID, because increasing drug resistance is being
reported [3236].
Treatment efficacy in the studies reviewed was restricted to
short-term clinical and microbiological cure. There are limited
data on the efficacy of any PID treatment regimen in the prevention of adverse reproductive sequelae. From the PEACH
study, we have previously reported that, among women with
In summary, a focus on reproductive and gynecologic morbidity, rather than on short-term clinical and microbiological
cure, is greatly needed. Whether currently prescribed PID antibiotic regimens are effective in the prevention of subsequent
reproductive morbidity is largely unknown. Arguably, longterm PID sequelae represent the most important treatment outcomes. Ultimately, microbe-specific and optimized treatment
needs to preserve fertility following PID and also prevent recurrent and persistent infection, ectopic pregnancy, and chronic
pain, improving the long-term prognosis for women who have
PID.
17.
18.
19.
20.
Acknowledgments
Potential conflicts of interest. C.L.H. and R.B.N.: no conflicts.
21.
References
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
ycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. South Med J 1993; 86:60410.
Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the
treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24:1708.
Ross JDC, Cronje S, Paszkowski T, et al. Moxifloxacin versus ofloxacin
plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Infect
2006; 82:44651.
Malhotra M, Sharma JB, Batra S, Arora R, Sharma S. Ciprofloxacintinidazole combination, fluconazole-azithromycin-secnidazole-kit and
doxycycline-metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian J Med Sci 2003; 57:54955.
Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared
with two standard multidrug regimens for the treatment of acute pelvic
inflammatory disease. J Int Med Res 2003; 31:4554.
Witte EH, Peters AA, Smit IB, et al. A comparison of pefloxacin/
metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol 1993; 50:1538.
Hemsell DL, Martens MG, Faro S, Gall S, McGregor JA. A multicenter
study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic
infections in hospitalized women. Clin Infect Dis 1997; 24(Suppl 2):
S22230.
Soper DE, Brockwell NJ, Dalton HP. Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. Am J
Obstet Gynecol 1992; 167:65360.
Peipert JF, Sweet RL, Walker CK, Kahn J, Rielly-Gauvin K. Evaluation
of ofloxacin in the treatment of laparoscopically documented acute
pelvic inflammatory disease (salpingitis). Infect Dis Obstet Gynecol
1999; 7:13844.
Rustomjee R, Kharsany AB, Connolly CA, Karim SS. A randomized
controlled trial of azithromycin versus doxycycline/ciprofloxacin for
the syndromic management of sexually transmitted infections in a
resource-poor setting. J Antimicrob Chemother 2002; 49:8758.
Piyadigamage A, Wilson J. Improvement in the clinical cure rate of
outpatient management of pelvic inflammatory disease following a
change in therapy. Sex Transm Infect 2005; 81:2335.
Simms I, Mallinson H, Peeling RW, et al. Risk factors associated with
pelvic inflammatory disease: a UK study. Int J STD AIDS 2002; 13:18.
Uno M, Deguchi T, Komeda H, et al. Mycoplasma genitalium in the
cervices of Japanese women. Sex Transm Dis 1997; 24:2846.
Goldstein EJ, Citron DM, Hunt GS, Hudspeth M, Merriam CV. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic
and anaerobic human and animal bite pathogens isolated from skin
and soft tissue infections in humans. Antimicrob Agents Chemother
1998; 42:112732.
Watt B, Brown FV. Is ciprofloxacin active against clinically important
anaerobes? J Antimicrob Chemother 1986; 17:60513.
Fernandes PB, Shipkowitz N, Bower RR, Jarvis KP, Weisz J, Chu DT.
In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria. J Antimicrob Chemother 1986; 18:693701.
Johnson SR, Sandul AL, Parekh M, Wang SA, Knapp JS, Trees DL.
Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. Int J Antimicrob Agents 2003; 21:4149.
McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria
gonorrhoeae with decreased susceptibility to Azithromycin in Kansas
City, Missouri, 1999 to 2000. Sex Transm Dis 2004; 31:738.
Dillon JA, Rubabaza JP, Benzaken AS, et al. Reduced susceptibility to
azithromycin and high percentages of penicillin and tetracycline re-
35.
36.
37.
38.
39.
40.
41.
42.
disease: results from the PID Evaluation and Clinical Health (PEACH)
randomized trial. Am J Obstet Gynecol 2002; 186:92937.
Haggerty CL, Schulz R, Ness RB. Lower quality of life among women
with chronic pelvic pain following pelvic inflammatory disease. Obstet
Gynecol 2003; 102:9349.
Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute
pelvic inflammatory disease. J Infect Dis 1988; 158:5107.
Tuffrey M, Woods C, Inman C, Ward M. The effect of a single oral
dose of azithromycin on chlamydial infertility and oviduct ultrastructure in mice. J Antimicrob Chemother 1994; 34:98999.
Patton DL, Sweeney YT, Stamm WE. Significant reduction in inflammatory response in the macaque model of chlamydial pelvic inflammatory disease with azithromycin treatment. J Infect Dis 2005; 192:
12935.